Sanofi Faces EU Antitrust Probe Over Efluelda Flu Vaccine Campaign
SNY•European Commission opened probe into Sanofi’s marketing of its enhanced flu vaccine Efluelda, suspecting it spread misleading claims to disparage competitor Fluad in Germany and France. If found in breach, Sanofi could face fines for abusing its dominant position in annual flu vaccine markets.
1. EU Opens Antitrust Probe
On June 26, the European Commission launched an antitrust investigation into Sanofi’s flu vaccine marketing, focusing on potential violations of competition rules. The inquiry targets the promotion of Efluelda and examines whether Sanofi’s actions distorted market competition within the EU.
2. Details of Alleged Marketing Practices
The probe centers on allegations that Sanofi ran a misleading communication campaign portraying the competitor’s Fluad vaccine as inferior, contrary to national vaccination recommendations. Campaign materials were directed at healthcare professionals in Germany and France, where Sanofi holds a strong market presence.
3. Sanofi's Response and Defense
Sanofi has denied any wrongdoing, asserting it has complied with all applicable laws and regulations. The company described the investigation as a procedural step and emphasized its commitment to fair competition and maintaining patient access to innovative vaccines.
4. Potential Penalties and Impact
If the commission confirms abuse of a dominant position, it could impose a significant fine on Sanofi and require commitments to remedy competitive concerns. The outcome may influence Sanofi’s market strategy and the positioning of Efluelda in future vaccination campaigns.
